Search

Your search keyword '"Farsang, C"' showing total 17 results
Start Over Author "Farsang, C" Publisher ovid technologies (wolters kluwer health)
17 results on '"Farsang, C"'

1. 2003 European Society of Hypertension???European Society of Cardiology guidelines for the management of arterial hypertension*

Author

MANCIA, GIUSEPPE, Rosei, EA, Cifkova, R, DeBacker, G, Erdine, S, Fagard, R, Farsang, C, Heagerty, AM, Kawecka Jaszcs, K, Kiowski, W, Kjeldsen, S, Luscher, T, McInnes, G, Mallion, JM, Brien, EO, Poulter, NR, Priori, SG, Rahn, KH, Rodicio, JL, Ruilope, LM, Safar, M, Staessen, JA, van Zwieten, P, Waeber, B, Williams, B, Zanchetti, A, Zannad, F., Mancia, G, Rosei, E, Cifkova, R, Debacker, G, Erdine, S, Fagard, R, Farsang, C, Heagerty, A, Kawecka Jaszcs, K, Kiowski, W, Kjeldsen, S, Luscher, T, Mcinnes, G, Mallion, J, Brien, E, Poulter, N, Priori, S, Rahn, K, Rodicio, J, Ruilope, L, Safar, M, Staessen, J, van Zwieten, P, Waeber, B, Williams, B, Zanchetti, A, and Zannad, F

Subjects
Physiology, optimal treatment hot, left-ventricular hypertrophy, end-point reduction, target-organ damage, Blood Pressure Determination, Guideline, Clinical practice, isolated systolic hypertension, Risk Assessment, Europe, ambulatory blood-pressure, randomized controlled trial, Hypertension, Internal Medicine, Humans, MED/09 - MEDICINA INTERNA, coronary-heart-disease, intima-media thickness, Cardiology and Cardiovascular Medicine, Risk Reduction Behavior, converting-enzyme-inhibition, Antihypertensive Agents
Abstract

ispartof: Journal of hypertension vol:21 issue:6 pages:1011-1053 ispartof: location:Netherlands status: published

Published
2003
Full Text
View/download PDF

3. METABOLIC PROFILE, PATTERNS OF METABOLIC CONTROL BY TREATMENT AND RELATIONSHIPS WITH BLOOD PRESSURE VALUES IN PATIENTS FROM CENTRAL AND EASTERN EUROPEAN COUNTRIES: THE BP-CARE METABOLIC STUDY

Author

Brambilla, G., primary, Seravalle, G., additional, Cifkova, R, additional, Laurent, S., additional, Narkiewicz, K., additional, Redon, J., additional, Farsang, C., additional, Bombelli, M., additional, Giannattasio, C., additional, Mancial, G., additional, and Grassi, G., additional

Published
2011
Full Text
View/download PDF

16. Randomized evaluation of a novel, fixed-dose combination of perindopril 3.5 mg/amlodipine 2.5 mg as a first-step treatment in hypertension

Author

Csaba Farsang, Gianfranco Parati, Andrejs Erglis, Irina Chazova, Yuriy Sirenko, Stéphane Laurent, Aleksandras Laucevičius, Laurent, S, Parati, G, Chazova, I, Sirenko, Y, Erglis, A, Laucevicius, A, and Farsang, C

Subjects
Adult, Male, Adolescent, Physiology, Fixed-dose combination, drug combination, Blood Pressure, Pharmacology, Fixed dose, law.invention, hypertension/drug therapy, Young Adult, Double-Blind Method, Randomized controlled trial, law, Internal Medicine, Perindopril, Humans, Medicine, In patient, Amlodipine, Antihypertensive Agents, Aged, business.industry, Middle Aged, Treatment Outcome, Blood pressure, Tolerability, Hypertension, antihypertensive agent, Drug Therapy, Combination, Female, Cardiology and Cardiovascular Medicine, business, medicine.drug
Abstract

OBJECTIVE:: To evaluate perindopril 3.5mg/amlodipine 2.5mg once daily, a novel fixed-dose combination adapted for first-step treatment in patients with hypertension. This fixed dose had to be equivalent to amlodipine 5mg in terms of blood pressure efficacy, but with an expected better tolerability profile. We selected two drugs with complementary modes of action, with doses chosen so that each drug would contribute similarly to the overall blood pressure-lowering effect METHODS:: An international, randomized, double-blind, placebo-controlled study with six equal parallel treatment arms and an 8-week randomized treatment period, whose design, clinical significance and non-inferiority criteria were in accordance with European guidelines. RESULTS:: In all, 1581 patients with mild-to-moderate uncomplicated hypertension (mean age 51.7 years) were randomized and 94.7% completed the study. The combination was statistically and clinically superior to placebo (between-group differences: SBP: -7.22mmHg, DBP: -4.12mmHg, P

Published
2015
Full Text
View/download PDF

17. Increased Soluble Fas Plasma Levels in Subjects at High Cardiovascular Risk

Author

Eduardo de Teresa, Jesús Egido, Allan Gaw, Pierre Martineau, Gonzalo Hernández, Csaba Farsang, Lawrence A. Leiter, José Luis Martín-Ventura, Anatoly Langer, Luis Miguel Blanco-Colio, Gian Franco Gensini, ACTFAST investigators, [Blanco-Colio,LM, Martín-Ventura,JL, Egido,J] Vascular Research Lab, Fundación Jimenéz Díaz, Autonoma University, Madrid, Spain. [ Teresa Galván,E de] University of Malaga & Hospital Universitario Virgen de la Victoria, Malaga, Spain. [Farsang,C] Department Med. Semmelweis University, Budapest, Hungary. [Gaw,A] University of Glasgow, Glasgow, UK. [Gensini,G] University of Florence, Careggi Hospital, Firenze, Italy. [Leiter,LA, Langer,A] University of Toronto & St-Michael’s Hospital, Toronto, ON, Canada. [Langer,A] Canadian Heart Research Centre, Toronto, ON, Canada. [Martineau,P] Medical Division, Pfizer Canada, Kirkland, QC, Canada. [R&D Department, Medical Division, Pfizer Spain (G.H.), Madrid, Spain. [Hernández,G] R&D Department, Medical Division, Pfizer Spain, Madrid, Spain., and This study was supported by Pfizer

Subjects
Male, Phenomena and Processes::Genetic Phenomena::Genetic Processes::Gene Expression Regulation [Medical Subject Headings], Atorvastatin, Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings], Fas ligand, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Mediana Edad, Risk Factors, soluble Fas, Prospective Studies, Regulación de la Expresión Génica, Masculino, Prospective cohort study, Enfermedades Cardiovasculares, Metabolic Syndrome, education.field_of_study, biology, Proteína C-Reactiva, Anticholesteremic Agents, Ácidos Heptanoicos, Femenino, atorvastatin, Estudios Prospectivos, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Albumins::C-Reactive Protein [Medical Subject Headings], Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::Cytokines::Tumor Necrosis Factors::Fas Ligand Protein [Medical Subject Headings], Middle Aged, Anticolesterolemiantes, Humanos, C-Reactive Protein, Cardiovascular Diseases, lipids (amino acids, peptides, and proteins), Female, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Death Domain::Antigens, CD95 [Medical Subject Headings], Cardiology and Cardiovascular Medicine, medicine.drug, medicine.medical_specialty, Fas Ligand Protein, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies [Medical Subject Headings], Population, Check Tags::Male [Medical Subject Headings], Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Azoles::Pyrroles [Medical Subject Headings], Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Antimetabolites::Hypolipidemic Agents::Anticholesteremic Agents [Medical Subject Headings], C-reactive protein, statins, Antígenos CD95, Diabetes mellitus, Internal medicine, Diabetes Mellitus, medicine, Humans, Pyrroles, cardiovascular diseases, fas Receptor, Named Groups::Persons::Age Groups::Adult::Aged [Medical Subject Headings], Relación Dosis-Respuesta a Droga, education, Diseases::Cardiovascular Diseases [Medical Subject Headings], Aged, Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Metabolic Syndrome X [Medical Subject Headings], Dose-Response Relationship, Drug, Diseases::Endocrine System Diseases::Diabetes Mellitus [Medical Subject Headings], business.industry, Vascular disease, Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Dose-Response Relationship, Drug [Medical Subject Headings], medicine.disease, Pirroles, Endocrinology, Check Tags::Female [Medical Subject Headings], Gene Expression Regulation, inflammation, Chemicals and Drugs::Lipids::Fatty Acids::Heptanoic Acids [Medical Subject Headings], Heptanoic Acids, biology.protein, Metabolic syndrome, Proteína Ligando Fas, Síndrome X Metabólico, business
Abstract

Objectives— Increasing evidence indicates that the Fas/Fas ligand interaction is involved in atherogenesis. We sought to analyze soluble Fas (sFas) and soluble Fas ligand (sFasL) concentrations in subjects at high cardiovascular risk and their modulation by atorvastatin treatment. Methods and Results— ACTFAST was a 12-week, prospective, multicenter, open-label trial which enrolled subjects (statin-free or statin-treated at baseline) with coronary heart disease (CHD), CHD-equivalent, or 10-year CHD risk >20%. Subjects with LDL-C between 100 to 220 mg/dL (2.6 to 5.7 mmol/L) and triglycerides ≤600 mg/dL (6.8 mmol/L) were assigned to a starting dose of atorvastatin (10 to 80 mg/d) based on LDL-C at screening. Of the 2117 subjects enrolled in ACTFAST, AIM sub-study included the 1078 statin-free patients. At study end, 85% of these subjects reached LDL-C target. Mean sFas levels were increased and sFasL were reduced in subjects at high cardiovascular risk compared with healthy subjects. Atorvastatin reduced sFas in the whole population as well as in patients with metabolic syndrome or diabetes. Minimal changes were observed in sFasL. Conclusions— sFas concentrations are increased and sFasL are decreased in subjects at high cardiovascular risk, suggesting that these proteins may be novel markers of vascular injury. Atorvastatin reduces sFas, indicating that short-term treatment with atorvastatin exhibits antiinflammatory effects in these subjects.

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results